Disease Knowledge and Treatment Strategies of Gout and Hyperuricemia
DOI:
https://doi.org/10.52461/ijnms.v1i3.870Keywords:
Gout, chronic arthritis, rheumatic disease, treatment strategies, hyperuricemiaAbstract
Gout is a striking introduction of uric acid aggravation. It is the most surely known and portrayed sort of joint pain. It is the study of disease transmission that is contemplated. New experiences into the pathophysiology of hyperuricemia and gouty arthritis; intense and constant consider a stunningly better comprehension of the disorder. The part of hereditary inclination is getting more apparent. The clinical image of gout is partitioned into asymptomatic hyperuricemia, intense gouty arthritis, intercritical period, and ongoing tophaceous gout. Diagnosis depends on laboratory tests and radiological highlights. The board of gout incorporates the executives of flares, ongoing gout and anticipation of flares, just as the executives of comorbidities. More up to date medicates in the pharmacological armamentarium are demonstrating fruitful and supplement more seasoned ones. Other significant focuses in its administration incorporate patient instruction, diet and way of life changes, just as suspension of hyperuricemic drugs. In this review article a point by point study has been done to explain the sickness interaction and related result just as the potential impediments and the executives of gout and hyperuricemia.
References
Jasvinder A.Singh and Angelo Gaffo.Gout epidemiology and comorbidities.Seminars in Arthritis and Rheumatism. 2020, 50(3): 11-16
Robinson, PC; Stamp, LK (May 2016). "The management of gout: Much has changed". Australian Family Physician. 45(5): 299–302
Seth, Rakhi; Kydd, Alison SR; Buchbinder, Rachelle; Bombardier, Claire; Edwards, Christopher J (2014-10-14). "Allopurinol for chronic gout". Cochrane Database of Systematic Reviews.
Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789–98.
Gandhi PK, Gentry WM, Ma Q, Bottorff MB. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm. 2015;21:165–75.
Roddy, E; Choi, HK (May 2014). "Epidemiology of gout". Rheumatic diseases clinics of North America. 40 (2): 155–75.
Zhang, T; Pope, JE (30 March 2017). "Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis". Rheumatology (Oxford, England). 56 (7): 1144–1153.
Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305–9.
John H.Y. Moi, Melonie K. Sriranganathan, Louise Falzon, Christopher J. Edwards, Désirée M. van der Heijde and Rachelle Buchbinder. (2014) Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews. J Rheumatol Suppl. 92: 26-32.
Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447–61.
Shekelle, P. G; Newberry, S. J; Fitzgerald, J. D; Motala, A; O'Hanlon, C. E; Tariq, A; Okunogbe, A; Han, D; Shanman, R (2017). "Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline". Annals of Internal Medicine. 166(1): 37–51.
Terkeltaub R (January 2010). "Update on gout: new therapeutic strategies and options". Nature Reviews Rheumatology. 6 (1): 30–8.
Kuriyama S, Maruyama Y, Nishio S, et al. Serum uric acid and the incidence of CKD and hypertension. ClinExpNephrol. 2015;19:1127–34.
Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649–62.
Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J ClinRheumatol. 2011;17:7–13.
Ashiq K, Latif A, Ashiq S, Sundus A. (2018). A systematic review on the prevalence, pathophysiology, diagnosis, management and treatment of gout (2007-2018). GSC Biological and Pharmaceutical Sciences, 5(1), 50-55.
Richette P, Bardin T (January 2010). "Gout". Lancet. 375(9711): 318–28.
Qaseem, A; McLean, RM; Starkey, M; Forciea, MA; Clinical Guidelines Committee of the American College of, Physicians. (3 January 2017). "Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 166 (1): 52–57.
Chizyński K, Rózycka M (2005). "Hyperuricemia". Pol. Merkur. Lekarski (in Polish). 19 (113): 693–6.
Abeles, A. M.; Pillinger, M. H. (March 8, 2010). "New therapeutic options for gout here and on the horizon". Journal of Musculoskeletal Medicine. Archived from the original on May 20, 2010.
Moi, JH; Sriranganathan, MK; Edwards, CJ; Buchbinder, R (4 November 2013). "Lifestyle interventions for acute gout". The Cochrane Database of Systematic Reviews. 11 (11): CD010519.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Natural Medicine and Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
You are free to:
• Share: copy and redistribute the material in any medium or format.
• Adapt: remix, transform, and build upon the material.
• Attribution: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial: You may not use the material for commercial purposes.
• No additional restrictions: You may not apply legal terms or technological measures, that legally restrict others from doing anything the license permits.
